Modernizing Eligibility Criteria for Molecularly Driven Trials
Authors:
- Edward S. KimEKEdward S. Kim
- David BernsteinDBDavid Bernstein
- Susan G. HilsenbeckSHSusan G. Hilsenbeck
- Christine H. ChungCCChristine H. Chung
- Adam P. DickerADAdam P. Dicker
- Jennifer L. ErsekJEJennifer L. Ersek
- Steven SteinSSSteven Stein
- Fadlo R. KhuriFKFadlo R. Khuri
- Earle BurgessEBEarle Burgess
- Kelly HuntKHKelly Hunt
- Percy IvyPIPercy Ivy
- Suanna S. BruinoogeSBSuanna S. Bruinooge
- 1 September 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (25) , 2815-2820
Abstract
As more clinical trials of molecularly targeted agents evolve, the number of eligibility criteria seems to be increasing. The importance and utility of eligibility criteria must be considered in the context of the fundamental goal of a clinical trial: to understand the risks and benefits of a treatment in the intended-use patient population. Although eligibility criteria are necessary to define the population under study and conduct trials safely, excessive requirements may severely restrict the population available for study, and often, this population is not reflective of the general population for which the drug would be prescribed. The American Society of Clinical Oncology Cancer Research Committee, which comprises academic faculty, industry representatives, and patient advocates, evaluated this issue. Evaluation results were mixed. Most physicians agreed that excessive eligibility criterias slow study enrollment rates and prolong the duration of enrollment; however, this hypothesis was difficult to validate with the data examined. We propose the organization of a public workshop, with input from regulatory bodies and key stakeholders, with the goal of developing an algorithmic approach to determining eligibility criteria for individual study protocols, which may help guide future investigators and companies in streamlining eligibility criteria in the era of molecularly driven therapy.Keywords
This publication has 21 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus SyndromeNew England Journal of Medicine, 2012
- A Novel Classification of Lung Cancer into Molecular SubtypesPLOS ONE, 2012
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Too Restrictive Exclusion Criteria in Advanced Stage Lung Cancer Therapeutic Trials: Are We Missing the Target?Journal of Thoracic Oncology, 2008
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- Restrictive Eligibility Limits Access to Newer Therapies in Non–Small-Cell Lung Cancer: The Implications of Eastern Cooperative Oncology Group 4599Clinical Lung Cancer, 2008
- Positron Emission Tomography Scans in Postchemotherapy Seminoma Patients With Residual Masses: A Retrospective Review From Indiana University HospitalJournal of Clinical Oncology, 2006
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004